Literature DB >> 6945906

Eastern Cooperative Oncology Group study of the cytochemistry of adult acute myeloid leukemia by correlation of subtypes with response and survival.

J M Bennett, C B Begg.   

Abstract

A study of over 300 adult patients with acute myeloid leukemia has been completed by member institutions of the Eastern Cooperative Oncology Group. A complete remission rate of 51% was achieved. The FAB classification was used with an overall concordance of 61% between investigators and the repository center. Acute monocytic leukemia (M5) and acute erythroleukemia (M6) accounted for 12% of the cases accessioned and had the worst median survival with no patients surviving 2 years. The longest response duration occurred in hypergranular promyelocytic leukemia (M3).

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6945906

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


  8 in total

1.  More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia.

Authors:  Guillermo Montalban-Bravo; Christopher B Benton; Sa A Wang; Farhad Ravandi; Tapan Kadia; Jorge Cortes; Naval Daver; Koichi Takahashi; Courtney DiNardo; Elias Jabbour; Gautam Borthakur; Marina Konopleva; Sherry Pierce; Carlos Bueso-Ramos; Keyur Patel; Steven Kornblau; Hagop Kantarjian; Ken H Young; Guillermo Garcia-Manero; Michael Andreeff
Journal:  Blood       Date:  2017-02-28       Impact factor: 22.113

2.  Correlation of surface marker expression with morphologically and immunologically defined subclasses of acute myeloid leukaemias.

Authors:  H G Drexler; M Menon; M Klein; N Bhoopalam; H L Messmore; J Minowada
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

3.  Association of leukocyte nadir with complete remission in Indonesian acute myeloid leukemia patients undergoing 7+3 remission induction chemotherapy.

Authors:  Dwi Wahyunianto Hadisantoso; Dody Ranuhardy; Wulyo Rajabto; Aulia Rizka; Lyana Setiawan; Ikhwan Rinaldi; Arif Mansjoer; Erni Juwita Nelwan; Hamzah Shatri
Journal:  F1000Res       Date:  2022-05-05

4.  Reproducibility of the morphological diagnostic criteria for acute myeloid leukemia: the GIMEMA group experience.

Authors:  G L Castoldi; V Liso; S Fenu; M L Vegna; F Mandelli
Journal:  Ann Hematol       Date:  1993-04       Impact factor: 3.673

5.  Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes.

Authors:  Xavier Calvo; Leonor Arenillas; Elisa Luño; Leonor Senent; Montserrat Arnan; Fernando Ramos; María Teresa Ardanaz; Carme Pedro; Mar Tormo; Julia Montoro; María Díez-Campelo; Beatriz Arrizabalaga; Blanca Xicoy; Santiago Bonanad; Andrés Jerez; Benet Nomdedeu; Ana Ferrer; Guillermo F Sanz; Lourdes Florensa
Journal:  Mod Pathol       Date:  2016-08-26       Impact factor: 7.842

6.  Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution.

Authors:  F P S Santos; S Faderl; G Garcia-Manero; C Koller; M Beran; S O'Brien; S Pierce; E J Freireich; X Huang; G Borthakur; C Bueso-Ramos; M de Lima; M Keating; J Cortes; H Kantarjian; F Ravandi
Journal:  Leukemia       Date:  2009-09-10       Impact factor: 11.528

7.  Acute erythroid leukemia is enriched in NUP98 fusions: a report from the Children's Oncology Group.

Authors:  Karen M Chisholm; Amy E Heerema-McKenney; John K Choi; Jenny Smith; Rhonda E Ries; Betsy A Hirsch; Susana C Raimondi; Todd A Alonzo; Yi-Cheng Wang; Richard Aplenc; Lillian Sung; Alan S Gamis; Soheil Meshinchi; Samir B Kahwash
Journal:  Blood Adv       Date:  2020-12-08

8.  The uniqueness of morphological features of pure erythroid leukemia in myeloid neoplasm with erythroid predominance: A reassessment using criteria revised in the 2016 World Health Organization classification.

Authors:  Po-Shen Ko; Yao-Chung Liu; Chiu-Mei Yeh; Jyh-Pyng Gau; Yuan-Bin Yu; Liang-Tsai Hsiao; Cheng-Hwai Tzeng; Po-Min Chen; Tzeon-Jye Chiou; Chia-Jen Liu; Jin-Hwang Liu
Journal:  PLoS One       Date:  2017-02-14       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.